| Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. | |
| | |
MedLine Citation:
|
PMID: 20038237 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We conducted a retrospective analysis on 168 adult patients with newly diagnosed, limited-stage (I and II) diffuse large B-cell lymphoma (DLBCL) treated from 1988 to 2004 with PROMECE-CYTABOM (P-C) plus involved-field radiation therapy (IF-RT). At the end of P-C, the overall response rate was 92%. Radiotherapy (RT) was delivered to 84% of cases. With a median follow-up of 95 months, overall survival (OS), relapse free survival (RFS), and failure free survival at 5 and 10 years was 84% and 77%, 81% and 75%, 71% and 67%, respectively. Age (>60 years, p = 0.002), serum albumin (<3.5 g/dL; p = 0.015), and RT (p < 0.001) were independent predictors of OS. For patients in complete remission the administration of RT didn't improve both RFS and OS. This study confirms that patients with localized aggressive lymphoma have a high chance of cure with anthracycline containing regimens. Though the regimen used to treat these patients does not contain rituximab, results are considered excellent both in terms of efficacy and safety. |
| | |
Authors:
|
Donato Mannina; Stefano Luminari; Alessandra Dondi; Giuseppe Polimeno; Luca Baldini; Caterina Stelitano; Francesco Merli; Matteo Dell'Olio; Paolo G Gobbi; Gianfranco Giglio; Elisa Barbolini; Maura Brugiatelli; Massimo Federico |
Related Documents
:
|
12788177 - Postmastectomy radiotherapy: patterns of recurrence and long-term disease control using... 10506617 - Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effect... 19277037 - Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcino... 14732887 - Guidelines for the treatment of malignant gliomas in elderly patients. 9075747 - Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorect... 15127417 - Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rh... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 51 ISSN: 1029-2403 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-12 Completed Date: 2010-11-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: England |
Other Details:
|
Languages: eng Pagination: 422-9 Citation Subset: IM |
Affiliation:
|
Divisione di Ematologia, Azienda Ospedaliera Papardo, Messina, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Bleomycin / therapeutic use Cyclophosphamide / therapeutic use Cytarabine / therapeutic use Disease-Free Survival Epirubicin / therapeutic use Etoposide / therapeutic use Female Follow-Up Studies Humans Lymphoma Lymphoma, Non-Hodgkin / drug therapy*, radiotherapy* Male Methotrexate / therapeutic use Middle Aged Multivariate Analysis Prednisone / therapeutic use Radiotherapy / methods Retrospective Studies Treatment Outcome Vincristine / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/ProMECE-CytaBOM protocol; 11056-06-7/Bleomycin; 147-94-4/Cytarabine; 33419-42-0/Etoposide; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 56420-45-2/Epirubicin; 57-22-7/Vincristine; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in n...
Next Document: Cerebrospinal Fluid Inflammatory Cytokines and Biomarkers of Injury Severity in Acute Human Spinal C...